Trials / Completed
CompletedNCT00069446
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
An Exploratory, Double-Blind, Randomized, Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, double blind, randomized, placebo-controlled study that will enroll approximately 50 adult subjects with Type 1 or Type 2 diabetes mellitus and chronic, diabetic foot ulcers. The study will be conducted at approximately 12 investigational sites in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuMAb VEGF (telbermin) |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2004-10-01
- Completion
- 2004-10-01
- First posted
- 2003-09-26
- Last updated
- 2017-05-11
Source: ClinicalTrials.gov record NCT00069446. Inclusion in this directory is not an endorsement.